BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 8
• 9
• 10
• 11
• 12
• 13

• Press Releases

  Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

  February 10, 2026

   · 

  2 min read
• Press Releases

  IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share

  February 10, 2026

   · 

  21 min read
• Press Releases

  Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share

  February 10, 2026

   · 

  21 min read
• Press Releases

  Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

  February 10, 2026

   · 

  14 min read
• Press Releases

  ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

  February 10, 2026

   · 

  11 min read
• Press Releases

  INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB

  February 10, 2026

   · 

  7 min read
• Press Releases

  Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

  February 10, 2026

   · 

  9 min read
• Press Releases

  BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease

  February 10, 2026

   · 

  7 min read
• Press Releases

  OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

  February 10, 2026

   · 

  8 min read
• Press Releases

  Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business

  February 10, 2026

   · 

  4 min read